Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after ...

Higher costs and issues with Russia led Vertex Pharmaceuticals to miss profit and sales estimates. Constellation Energy beat revenue forecasts and reiterated its full-year earnings guidance on ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) have been very resilient in the last six months. There was that brief trip to just below $400 per share in December after suzetrigine (Journavx ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...

لكن جهاز Torras PowerCircle Qi2، والذي يبلغ سعره ... ستغير مفهوم الهواتف الذكية فهو لا يعمل فقط كشاحن لاسلكي بقدرة 15 ...

In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Vertex, Inc. (NASDAQ:VERX). Vertex, Inc. (NASDAQ:VERX) offers enterprise tax technology solutions ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Immersive training devices from Vertex Solutions are destined for the U.S. Air Force for the Fighter Bomber Fundamentals program. [Courtesy: Vertex Solutions] Vertex Solutions, a small business ...